A severe case of refractory esophageal stenosis induced by nivolumab and responding to tocilizumab therapy

A severe case of refractory esophageal stenosis induced by nivolumab and responding to tocilizumab therapy

Abstract Background The prevalence of esophageal stenosis caused by immune checkpoint inhibitors in the context of induced immune mucositis and esophagitis is extremely rare. Case presentation We report the case of a patient with stage IV pulmonary adenocarcinoma treated for 6 months with nivolumab...

Full description

Bibliographic Details
Main Authors: Alice Horisberger, Stefano La Rosa, Jean-Philippe Zurcher, Stefan Zimmermann, Francois Spertini, George Coukos, Michel Obeid
Format: Article
Language:English
Published: BMJ Publishing Group 2018-12-01
Series:Journal for ImmunoTherapy of Cancer
Subjects:
Checkpoint inhibitors
Immune-related adverse events
Nivolumab
PD-1
Esophageal stenosis
Online Access:http://link.springer.com/article/10.1186/s40425-018-0481-0

Internet

http://link.springer.com/article/10.1186/s40425-018-0481-0

Similar Items